Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
Shirley D’Sa, Professor of Haematology at United KingdomUnited Kingdom, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Hematology Reports, adding:
”Treatment options following BTK inhibitor failure in Waldenström macroglobulinaemia (WM) remain an important unmet need in our field.
Our recently published article explores the role of bortezomib-based therapy in patients who have progressed following BTKi treatment, providing valuable real-world evidence in an area where prospective data remain limited.
As the therapeutic landscape of WM continues to evolve—with non-covalent BTK inhibitors, BTK degraders, BCL2 inhibitors, bispecific antibodies and cellular therapies all under investigation—it is important not to overlook the potential utility of established agents such as proteasome inhibitors.
The paper contributes to the growing discussion around treatment sequencing in WM and the question many of us increasingly face in clinical practice: what comes after BTKi?
An interesting read for anyone involved in the care of patients with WM and related IgM disorders.”
Title: Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Authors: Tahanzaib Khwaja, Nicole Japzon, Simona Gatto, Jindriska Lindsay, Charalampia Kyriakou, Shirley D’Sa
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 6, 2026, 23:30Yazan Abou-Ismail: Insights on A Snail-Derived Potential Anticoagulant with Possibly Improved Bleeding Profile
-
Jun 6, 2026, 18:40Igor Carvalho de Oliveira: The Hidden Genetic Risk Behind Early Heart Attacks and Strokes
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published